Skip to main content
Erschienen in: Supportive Care in Cancer 9/2017

11.04.2017 | Original Article

The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas

verfasst von: Xiao Jun Wang, Denise Yun Ting Goh, Sreemanee Raaj Dorajoo, Alexandre Chan

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aims to develop and validate a prognostic model (PROMASCC) by incorporating the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N) elements, with the Multinational Association of Supportive Care in Cancer (MASCC) risk index, for identifying low-risk patients with febrile neutropenia (FN) for developing serious complications.

Methods

This was a single-center, cross-sectional observational study. Either English or Chinese versions of the FACT-N were administered to the eligible patients according to their language preference within 7 days of FN onset. Univariate analyses and multivariate analyses were performed to construct the PROMASCC model. The prognostic performance was compared between the PROMASCC model and MASCC risk index. The internal validation of the PROMASCC model was examined by bootstrapping technique.

Results

From August 2014 to April 2016, a total of 120 eligible patients were included in this study. In the univariate analyses, only the malaise subscale score has been significantly associated with the favorable outcome (without complications) (P = 0.024). Compared to the MASCC risk index, the PROMASCC model has shown advantages on the improved specificity (64.3 vs. 38.1%) and positive predictive value (81.0 vs. 73.7%), lower misclassification rate (24.2 vs. 25.8%), and increased area under receiver-operating characteristic curve (0.732 vs. 0.658). The bootstrapping procedure estimates the optimism-corrected area for the PROMASCC model to be 0.731 (95% CI 0.648 to 0.814).

Conclusions

This study has developed and validated a PROMASCC model and demonstrated that additional measurement on patient’s fatigue level could improve the risk stratification of patients with FN.
Literatur
1.
Zurück zum Zitat Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, Legg JC, Kaye JA (2013) A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ 16(6):720–735. doi:10.3111/13696998.2013.782034 CrossRefPubMed Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, Legg JC, Kaye JA (2013) A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ 16(6):720–735. doi:10.​3111/​13696998.​2013.​782034 CrossRefPubMed
2.
Zurück zum Zitat Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Annals of oncology : official journal of the European Society for Medical Oncology 27(suppl 5):v111–v118. doi:10.1093/annonc/mdw325 CrossRef Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Annals of oncology : official journal of the European Society for Medical Oncology 27(suppl 5):v111–v118. doi:10.​1093/​annonc/​mdw325 CrossRef
3.
Zurück zum Zitat National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) (2016) Prevention and Treatment of Cancer-Related Infections. v2 National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) (2016) Prevention and Treatment of Cancer-Related Infections. v2
4.
Zurück zum Zitat Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K (2000) The multinational Association for Supportive Care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051CrossRefPubMed Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K (2000) The multinational Association for Supportive Care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051CrossRefPubMed
5.
Zurück zum Zitat Talcott JA, Finberg R, Mayer RJ, Goldman L (1988) The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148(12):2561–2568CrossRefPubMed Talcott JA, Finberg R, Mayer RJ, Goldman L (1988) The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148(12):2561–2568CrossRefPubMed
6.
Zurück zum Zitat Carmona-Bayonas A, Jiménez-Fonseca P, Echaburu JV, Antonio M, Font C, Biosca M, Ramchandani A, Martínez J, Cubero JH, Espinosa J (2015) Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. Journal of Clinical Oncology:JCO. 2014.2057. 2347 Carmona-Bayonas A, Jiménez-Fonseca P, Echaburu JV, Antonio M, Font C, Biosca M, Ramchandani A, Martínez J, Cubero JH, Espinosa J (2015) Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. Journal of Clinical Oncology:JCO. 2014.2057. 2347
7.
Zurück zum Zitat Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 10(2):316–322CrossRef Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 10(2):316–322CrossRef
8.
Zurück zum Zitat de Souza VL, Serufo JC, da Costa Rocha MO, Costa RN, Duarte RC (2008) Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 16(7):841–846. doi:10.1007/s00520-007-0347-3 CrossRef de Souza VL, Serufo JC, da Costa Rocha MO, Costa RN, Duarte RC (2008) Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 16(7):841–846. doi:10.​1007/​s00520-007-0347-3 CrossRef
9.
Zurück zum Zitat Baskaran ND, Gan GG, Adeeba K (2008) Applying the multinational Association for Supportive Care in cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Ann Hematol 87(7):563–569. doi:10.1007/s00277-008-0487-7 CrossRefPubMed Baskaran ND, Gan GG, Adeeba K (2008) Applying the multinational Association for Supportive Care in cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Ann Hematol 87(7):563–569. doi:10.​1007/​s00277-008-0487-7 CrossRefPubMed
10.
Zurück zum Zitat Cherif H, Johansson E, Bjorkholm M, Kalin M (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91(2):215–222PubMed Cherif H, Johansson E, Bjorkholm M, Kalin M (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91(2):215–222PubMed
11.
Zurück zum Zitat Paesmans M, Rapoport B, Maertens J, Slabber C, Ferrant A, Wingard J, Aoun M, Dubreucq L, Plehiers B (2003) Klastersky J Multicentric prospective validation of the MASCC risk-index score for identification of febrile neutropenic cancer patients at low-risk for serious medical complications. In: Proc Am Soc Clin Oncol, p 556 Paesmans M, Rapoport B, Maertens J, Slabber C, Ferrant A, Wingard J, Aoun M, Dubreucq L, Plehiers B (2003) Klastersky J Multicentric prospective validation of the MASCC risk-index score for identification of febrile neutropenic cancer patients at low-risk for serious medical complications. In: Proc Am Soc Clin Oncol, p 556
12.
Zurück zum Zitat Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the multinational Association of Supportive Care of cancer (MASCC) risk-index score. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 12(8):555–560. doi:10.1007/s00520-004-0614-5 CrossRef Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the multinational Association of Supportive Care of cancer (MASCC) risk-index score. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 12(8):555–560. doi:10.​1007/​s00520-004-0614-5 CrossRef
13.
Zurück zum Zitat Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 52(4):e56–e93. doi:10.1093/cid/cir073 CrossRef Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 52(4):e56–e93. doi:10.​1093/​cid/​cir073 CrossRef
14.
Zurück zum Zitat Klastersky J, Paesmans M (2013) The multinational Association for Supportive Care in cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 21(5):1487–1495CrossRefPubMed Klastersky J, Paesmans M (2013) The multinational Association for Supportive Care in cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 21(5):1487–1495CrossRefPubMed
15.
Zurück zum Zitat Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M, Barette M (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 24(25):4129–4134. doi:10.1200/jco.2005.03.9909 CrossRef Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M, Barette M (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 24(25):4129–4134. doi:10.​1200/​jco.​2005.​03.​9909 CrossRef
16.
Zurück zum Zitat Fehnel S, DeMuro C, McLeod L, Coon C, Gnanasakthy A (2013) US FDA patient-reported outcome guidance: great expectations and unintended consequences. Expert Review of Pharmacoeconomics & Outcomes Research 13(4):441–446. doi:10.1586/14737167.2013.814957 CrossRef Fehnel S, DeMuro C, McLeod L, Coon C, Gnanasakthy A (2013) US FDA patient-reported outcome guidance: great expectations and unintended consequences. Expert Review of Pharmacoeconomics & Outcomes Research 13(4):441–446. doi:10.​1586/​14737167.​2013.​814957 CrossRef
17.
Zurück zum Zitat Greenhalgh J (2009) The applications of PROs in clinical practice: what are they, do they work, and why? Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 18(1):115–123. doi:10.1007/s11136-008-9430-6 CrossRef Greenhalgh J (2009) The applications of PROs in clinical practice: what are they, do they work, and why? Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 18(1):115–123. doi:10.​1007/​s11136-008-9430-6 CrossRef
18.
Zurück zum Zitat Etkind SN, Daveson BA, Kwok W, Witt J, Bausewein C, Higginson IJ, Murtagh FE (2015) Capture, transfer, and feedback of patient-centered outcomes data in palliative care populations: does it make a difference? A systematic review. J Pain Symptom Manag 49(3):611–624. doi:10.1016/j.jpainsymman.2014.07.010 CrossRef Etkind SN, Daveson BA, Kwok W, Witt J, Bausewein C, Higginson IJ, Murtagh FE (2015) Capture, transfer, and feedback of patient-centered outcomes data in palliative care populations: does it make a difference? A systematic review. J Pain Symptom Manag 49(3):611–624. doi:10.​1016/​j.​jpainsymman.​2014.​07.​010 CrossRef
19.
Zurück zum Zitat Gotay CC, Kawamoto CT, Bottomley A, Efficace F (2008) The prognostic significance of patient-reported outcomes in cancer clinical trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(8):1355–1363. doi:10.1200/jco.2007.13.3439 CrossRef Gotay CC, Kawamoto CT, Bottomley A, Efficace F (2008) The prognostic significance of patient-reported outcomes in cancer clinical trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(8):1355–1363. doi:10.​1200/​jco.​2007.​13.​3439 CrossRef
20.
Zurück zum Zitat Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, Osoba D, Bjordal K, Bottomley A (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. The Lancet Oncology 10(9):865–871. doi:10.1016/s1470-2045(09)70200-1 CrossRefPubMed Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, Osoba D, Bjordal K, Bottomley A (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. The Lancet Oncology 10(9):865–871. doi:10.​1016/​s1470-2045(09)70200-1 CrossRefPubMed
22.
Zurück zum Zitat Farkas J, Kosnik M, Flezar M, Suskovic S, Lainscak M (2010) Self-rated health predicts acute exacerbations and hospitalizations in patients with COPD. Chest Journal 138(2):323–330CrossRef Farkas J, Kosnik M, Flezar M, Suskovic S, Lainscak M (2010) Self-rated health predicts acute exacerbations and hospitalizations in patients with COPD. Chest Journal 138(2):323–330CrossRef
23.
Zurück zum Zitat Wagner LI, Beaumont JL, Ding B, Malin J, Peterman A, Calhoun E, Cella D (2008) Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the functional assessment of cancer therapy-neutropenia (FACT-N). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 16(1):47–56. doi:10.1007/s00520-007-0270-7 CrossRef Wagner LI, Beaumont JL, Ding B, Malin J, Peterman A, Calhoun E, Cella D (2008) Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the functional assessment of cancer therapy-neutropenia (FACT-N). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 16(1):47–56. doi:10.​1007/​s00520-007-0270-7 CrossRef
25.
Zurück zum Zitat Altman DG, Lausen B, Sauerbrei W, Schumacher M (1994) Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86(11):829–835CrossRefPubMed Altman DG, Lausen B, Sauerbrei W, Schumacher M (1994) Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86(11):829–835CrossRefPubMed
26.
Zurück zum Zitat Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD (2001) Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54(8):774–781CrossRefPubMed Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD (2001) Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54(8):774–781CrossRefPubMed
27.
Zurück zum Zitat Steyerberg E (2008) Clinical prediction models: a practical approach to development, validation, and updating. Springer Science & Business Media Steyerberg E (2008) Clinical prediction models: a practical approach to development, validation, and updating. Springer Science & Business Media
28.
Zurück zum Zitat Lainscak M, Farkas J, Inkrot S, Gelbrich G, Neskovic AN, Rau T, Tahirovic E, Topper A, Apostolovic S, Haverkamp W, Herrmann-Lingen C, Anker SD, Dungen HD (2013) Self-rated health predicts adverse events during beta-blocker treatment: the CIBIS-ELD randomised trial analysis. Int J Cardiol 163(1):87–92. doi:10.1016/j.ijcard.2011.05.037 CrossRefPubMed Lainscak M, Farkas J, Inkrot S, Gelbrich G, Neskovic AN, Rau T, Tahirovic E, Topper A, Apostolovic S, Haverkamp W, Herrmann-Lingen C, Anker SD, Dungen HD (2013) Self-rated health predicts adverse events during beta-blocker treatment: the CIBIS-ELD randomised trial analysis. Int J Cardiol 163(1):87–92. doi:10.​1016/​j.​ijcard.​2011.​05.​037 CrossRefPubMed
29.
Zurück zum Zitat Efficace F, Gaidano G, Breccia M, Voso MT, Cottone F, Angelucci E, Caocci G, Stauder R, Selleslag D, Sprangers M, Platzbecker U, Ricco A, Sanpaolo G, Beyne-Rauzy O, Buccisano F, Palumbo GA, Bowen D, Nguyen K, Niscola P, Vignetti M, Mandelli F (2015) Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. The Lancet Oncology 16(15):1506–1514. doi:10.1016/s1470-2045(15)00206-5 CrossRefPubMed Efficace F, Gaidano G, Breccia M, Voso MT, Cottone F, Angelucci E, Caocci G, Stauder R, Selleslag D, Sprangers M, Platzbecker U, Ricco A, Sanpaolo G, Beyne-Rauzy O, Buccisano F, Palumbo GA, Bowen D, Nguyen K, Niscola P, Vignetti M, Mandelli F (2015) Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. The Lancet Oncology 16(15):1506–1514. doi:10.​1016/​s1470-2045(15)00206-5 CrossRefPubMed
30.
Zurück zum Zitat Zikos E, Coens C, Quinten C, Ediebah DE, Martinelli F, Ghislain I, King MT, Gotay C, Ringash J, Velikova G, Reeve BB, Greimel E, Cleeland CS, Flechtner H, Taphoorn MJ, Weis J, Schmucker-von Koch J, Sprangers MA, Bottomley A (2016) The added value of analyzing pooled health-related quality of life data: a review of the EORTC PROBE initiative. J Natl Cancer Inst 108(5). doi:10.1093/jnci/djv391 Zikos E, Coens C, Quinten C, Ediebah DE, Martinelli F, Ghislain I, King MT, Gotay C, Ringash J, Velikova G, Reeve BB, Greimel E, Cleeland CS, Flechtner H, Taphoorn MJ, Weis J, Schmucker-von Koch J, Sprangers MA, Bottomley A (2016) The added value of analyzing pooled health-related quality of life data: a review of the EORTC PROBE initiative. J Natl Cancer Inst 108(5). doi:10.​1093/​jnci/​djv391
32.
Zurück zum Zitat Rodrigues AR, Trufelli DC, Fonseca F, del Giglio A (2015) Fatigue in patients with advanced terminal cancer correlates with inflammation, poor quality of life and sleep, and anxiety/depression. American Journal of Hospice and Palliative Medicine. doi:10.1177/1049909115603055 Rodrigues AR, Trufelli DC, Fonseca F, del Giglio A (2015) Fatigue in patients with advanced terminal cancer correlates with inflammation, poor quality of life and sleep, and anxiety/depression. American Journal of Hospice and Palliative Medicine. doi:10.​1177/​1049909115603055​
33.
Zurück zum Zitat de Raaf PJ, Sleijfer S, Lamers CH, Jager A, Gratama JW, van der Rijt CC (2012) Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative study. Cancer 118(23):6005–6011. doi:10.1002/cncr.27613 CrossRefPubMed de Raaf PJ, Sleijfer S, Lamers CH, Jager A, Gratama JW, van der Rijt CC (2012) Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative study. Cancer 118(23):6005–6011. doi:10.​1002/​cncr.​27613 CrossRefPubMed
34.
Zurück zum Zitat Gilbody SM, House AO, Sheldon TA (2001) Routinely administered questionnaires for depression and anxiety: systematic review. BMJ 322(7283):406–409CrossRefPubMedPubMedCentral Gilbody SM, House AO, Sheldon TA (2001) Routinely administered questionnaires for depression and anxiety: systematic review. BMJ 322(7283):406–409CrossRefPubMedPubMedCentral
35.
Metadaten
Titel
The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas
verfasst von
Xiao Jun Wang
Denise Yun Ting Goh
Sreemanee Raaj Dorajoo
Alexandre Chan
Publikationsdatum
11.04.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2017
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3696-6

Weitere Artikel der Ausgabe 9/2017

Supportive Care in Cancer 9/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.